Yeah a number of factors here...Bene in my view are keen as...

Yeah a number of factors here...

Bene in my view are keen as mustard...but their role comes more into play later on once we have approvals in and the license to sell! They are still very close to PAR and follow it.

FDA have been bitten before, opioids, they also will have a sense on how much this could scale so they are checking everything, particularly safety to the n^th degree.

Other parties still have drugs that haven't worked out quite like they were supposed to like Tanezumab and a few others (eg Biosplice's Lorecivivint) on their minds, they want and need more certainty before they potentially strike, specially when we are claiming to have quite the wonder-drug with immaculate safety profile.

Then there is the share market, wary that we are low in funds and wondering how we get out of this, how do we fund a P3...what is the gap. The share market doesn't like uncertainty and will keep us low till it's resolved.